Patents Assigned to ModernaTX, Inc.
  • Publication number: 20230020362
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: May 5, 2022
    Publication date: January 19, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • Publication number: 20230000970
    Abstract: The disclosure provides RNA vaccines for seasonal influenza virus as well as methods of using the vaccines.
    Type: Application
    Filed: January 10, 2022
    Publication date: January 5, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Raffael Nachbagauer, Carole Henry, Patricia Jorquera
  • Patent number: 11541113
    Abstract: The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: January 3, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John
  • Publication number: 20220409720
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 29, 2022
    Applicant: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Publication number: 20220401551
    Abstract: Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.
    Type: Application
    Filed: June 14, 2022
    Publication date: December 22, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Jack F. Kramarczyk, Kimberly Hassett, Shinu John, Phil White, Andrea Carfi
  • Patent number: 11524023
    Abstract: Provided herein are compositions and methods of reducing adduct formation.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: December 13, 2022
    Assignee: MODERNATX, INC.
    Inventors: Meredith Packer, Dipendra Gyawali, Serenus Hua, Gabor Butora, Gregory John Mercer
  • Publication number: 20220378904
    Abstract: Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 1, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
  • Patent number: 11504337
    Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: November 22, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Paolo Martini, Vladimir Presnyak, Kerry Benenato, Stephen Hoge, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe
  • Patent number: 11497807
    Abstract: Provide herein are Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: November 15, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
  • Publication number: 20220347292
    Abstract: Aspects of the invention relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines comprising hCMV antigenic polypeptides gH, gL, UL128, UL130, UL131 A and gB formulated in lipid nanoparticles, wherein the antigen-specific immune response to hCMV results in neutralizing antibodies that have i) a geometric mean titer of at least 3-fold against epithelial cell infection or ii) a geometric mean ratio of 9-41 against epithelial cell infection or iii) a geometric mean ratio of 4-8-fold against fibroblast infection.
    Type: Application
    Filed: September 11, 2020
    Publication date: November 3, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Lori Panther, Shinu John, Tal Zaks
  • Publication number: 20220348900
    Abstract: Provided herein, in some embodiments, are methods of purifying low-salt RNA compositions using denaturing oligo-dT chromatography.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 3, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Michael Shamashkin, Matthew Scott, Peter Wojciechowski
  • Patent number: 11484590
    Abstract: The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: November 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
  • Patent number: 11485960
    Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: November 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
  • Patent number: 11485972
    Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Melissa J. Moore, Caroline Köhrer, Ruchi Jain, Vladimir Presnyak
  • Publication number: 20220339185
    Abstract: Provided herein are compositions and methods of reducing adduct formation.
    Type: Application
    Filed: June 27, 2022
    Publication date: October 27, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Meredith Packer, Dipendra Gyawali, Serenus Hua, Gabor Butora, Gregory John Mercer
  • Publication number: 20220323572
    Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: November 3, 2021
    Publication date: October 13, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Mihir Metkar, Valdimir Presnyak
  • Patent number: 11464848
    Abstract: The disclosure describes respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 11, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
  • Publication number: 20220290125
    Abstract: Provided herein, in some embodiments, are methods of purifying a nucleic acid preparation. The methods may comprise contacting a nucleic acid preparation comprising messenger ribonucleic acid with an RNase III enzyme that is immobilized on a solid support and binds to double-stranded RNA contaminants.
    Type: Application
    Filed: June 2, 2022
    Publication date: September 15, 2022
    Applicant: ModernaTx, Inc.
    Inventor: Edward J. Miracco
  • Patent number: 11434486
    Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: September 6, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Gabor Butora, Andrew W. Fraley, Edward John Miracco, Jennifer Nelson, Amy Rhoden Smith, Matthew Stanton
  • Publication number: 20220265856
    Abstract: This disclosure relates to mRNA therapy for the treatment of propionic acidemia (PA). mRNAs for use in the invention, when administered in vivo, encode human propionyl-CoA carboxylase alpha (PCCA) and/or human propionyl-CoA carboxylase beta (PCCB), and isoforms thereof, functional fragments thereof, and fusion proteins comprising PCCA and/or PCCB. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of propionyl-CoA carboxylase (PCC) expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of disease-associated toxic metabolites associated with deficient PCCA or PCCB activity, in subjects.
    Type: Application
    Filed: November 21, 2018
    Publication date: August 25, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Lei Jiang, Lin Tung Guey, Paolo G.V. Martini, Vladimir Presnyak